Tadalafil tops in erectile dysfunction
- PDF / 139,620 Bytes
- 1 Pages / 623.591 x 841.847 pts Page_size
- 19 Downloads / 174 Views
Tadalafil
Placebo
Up to 80 years of age (up to 100 years of Cost ($US) 56 000 62 000 (93 000) (96 000) Effectiveness 133.45 131.44 (QALY) (158.66) (156.69) Cost 419.63 471.70 effectiveness (586.16) (612.67) ($US/QALY) Incremental dominateda cost effectiveness ($US/QALY) a
Vardenafil
Sildenafil
age) 68 000 (110 000) 132.39 (157.15) 513.63 (699.97)
90 000 (140 000) 130.53 (154.61) 689.55 (905.50)
dominated
dominated
Dominated strategies cost more and were less effective than tadalafil.
The total treatment cost of tadalafil was $US56 000, compared with $US68 000 for vardenafil, the second most cost effective option. The use of tadalafil produced the greatest QALY gains of all three treatments. The authors note that no treatment was a better option if there were no costs involved with managing treatmentrelated morbidity long-term. Sensitivity analysis revealed that when thresholds of 66.65% effectiveness for tadalafil or 73.54% effectiveness for vardenafil were used, tadalafil lost its dominance, making vardenafil a better option under these scenarios. * Costs were calculated from a societal perspective, and included those associated with drugs, services, care delivery, and lost productivity. Roy S, et al. Cost-effectiveness analysis of oral pharmacological treatments of erectile dysfunction. Value in Health 9: 51 (plus poster) abstr. PIH3, No. 3, May801066574 Jun 2006
1173-5503/10/0508-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved
PharmacoEconomics & Outcomes News 29 Jul 2006 No. 508
1
Data Loading...
